The FDA’s unapproved drug initiative has had an impact on catheter lock therapy for home infusion patients. Patients who require a central venous access device (CVAD) are at a significant risk for catheter-associated bloodstream infections. The lack of options and high cost have created an urgent need in the U.S. for FDA-approved central line catheter lock solutions.
In this white paper learn about:
- Challenges and costs of Ethanol Lock Therapy (ELT)
- Need for FDA-approved alternative lock solutions
Related healthcare insights
Article
Smart clinical strategy: meet patient needs with expanding sites of care
Stay up to date on our Specialty and Infusion Pharmacy offerings and get important industry developments delivered directly to your inbox.
Article
Optum helps providers keep patients on therapy during travel, relocation or disruption through coordinated, nationwide infusion and specialty pharmacy support.